A retrospective cohort study identifying the principal pathological features useful in the diagnosis of inclusion body myositis

Objective The current pathological diagnostic criteria for sporadic inclusion body myositis (IBM) lack sensitivity. Using immunohistochemical techniques abnormal protein aggregates have been identified in IBM, including some associated with neurodegenerative disorders. Our objective was to investigate the diagnostic utility of a number of markers of protein aggregates together with mitochondrial and inflammatory changes in IBM. Design Retrospective cohort study. The sensitivity of pathological features was evaluated in cases of Griggs definite IBM. The diagnostic potential of the most reliable features was then assessed in clinically typical IBM with rimmed vacuoles (n=15), clinically typical IBM without rimmed vacuoles (n=9) and IBM mimics—protein accumulation myopathies containing rimmed vacuoles (n=7) and steroid-responsive inflammatory myopathies (n=11). Setting Specialist muscle services at the John Radcliffe Hospital, Oxford and the National Hospital for Neurology and Neurosurgery, London. Results Individual pathological features, in isolation, lacked sensitivity and specificity. However, the morphology and distribution of p62 aggregates in IBM were characteristic and in a myopathy with rimmed vacuoles, the combination of characteristic p62 aggregates and increased sarcolemmal and internal major histocompatibility complex class I expression or endomysial T cells were diagnostic for IBM with a sensitivity of 93% and specificity of 100%. In an inflammatory myopathy lacking rimmed vacuoles, the presence of mitochondrial changes was 100% sensitive and 73% specific for IBM; characteristic p62 aggregates were specific (91%), but lacked sensitivity (44%). Conclusions We propose an easily applied diagnostic algorithm for the pathological diagnosis of IBM. Additionally our findings support the hypothesis that many of the pathological features considered typical of IBM develop later in the disease, explaining their poor sensitivity at disease presentation and emphasising the need for revised pathological criteria to supplement the clinical criteria in the diagnosis of IBM.

[1]  K. Moons,et al.  Rimmed vacuoles and the added value of SMI-31 staining in diagnosing sporadic inclusion body myositis , 2001, Neuromuscular Disorders.

[2]  David Hilton-Jones,et al.  Clinical assessment determines the diagnosis of inclusion body myositis independently of pathological features , 2013, Journal of Neurology, Neurosurgery & Psychiatry.

[3]  David Hilton-Jones,et al.  International Workshop on Inclusion Body Myositis held at the Institute of Myology, Paris, on 29 May 2009 , 2010, Neuromuscular Disorders.

[4]  David Hilton-Jones,et al.  Long-term observational study of sporadic inclusion body myositis. , 2011, Brain : a journal of neurology.

[5]  S. Marie,et al.  International consensus on a proposed score system for muscle biopsy evaluation in patients with juvenile dermatomyositis: a tool for potential use in clinical trials. , 2007, Arthritis and rheumatism.

[6]  I. Ferrer,et al.  Molecular pathology of myofibrillar myopathies , 2008, Expert Reviews in Molecular Medicine.

[7]  Andrew G. Engel,et al.  αB-Crystallin immunolocalization yields new insights into inclusion body myositis , 2000, Neurology.

[8]  G. Gronseth,et al.  Inclusion body myositis: Clinical and pathological boundaries , 1996, Annals of neurology.

[9]  Margaret M. Esiri,et al.  Ubiquitinated inclusions in inclusion-body myositis patients are immunoreactive for cathepsin D but not β-amyloid , 1995, Neuroscience Letters.

[10]  Shin J. Oh,et al.  Rimmed vacuoles of inclusion body myositis and oculopharyngeal muscular dystrophy contain amyloid precursor protein and lysosomal markers , 1993, Brain Research.

[11]  Frank L Mastaglia,et al.  Inclusion body myositis: current pathogenetic concepts and diagnostic and therapeutic approaches , 2007, The Lancet Neurology.

[12]  A. Hiniker,et al.  Comparative utility of LC3, p62 and TDP-43 immunohistochemistry in differentiation of inclusion body myositis from polymyositis and related inflammatory myopathies , 2013, Acta neuropathologica communications.

[13]  Steven A Greenberg,et al.  Theories of the Pathogenesis of Inclusion Body Myositis , 2010, Current rheumatology reports.

[14]  Timothy Day,et al.  Prevalence of sporadic inclusion body myositis and factors contributing to delayed diagnosis , 2008, Journal of Clinical Neuroscience.

[15]  W. Engel,et al.  In sporadic inclusion body myositis muscle fibres TDP‐43‐positive inclusions are less frequent and robust than p62 inclusions, and are not associated with paired helical filaments , 2011, Neuropathology and applied neurobiology.

[16]  R. Gherardi,et al.  Inclusion body myositis in French patients. A clinicopathological evaluation , 1990, Neuropathology and applied neurobiology.

[17]  Andrew G Engel,et al.  Correlation of muscle biopsy, clinical course, and outcome in PM and sporadic IBM , 2008, Neurology.

[18]  A. Engel,et al.  Monoclonal antibody analysis of mononuclear cells in myopathies. I: Quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cells , 1984, Annals of neurology.

[19]  F L Mastaglia,et al.  Sporadic inclusion body myositis: Phenotypic variability and influence of HLA-DR3 in a cohort of 57 Australian cases , 2008, Journal of Neurology, Neurosurgery, and Psychiatry.

[20]  A. Pestronk,et al.  TDP-43 accumulation in inclusion body myopathy muscle suggests a common pathogenic mechanism with frontotemporal dementia , 2008, Journal of Neurology, Neurosurgery, and Psychiatry.

[21]  I. Nonaka,et al.  Rimmed Vacuoles in Becker Muscular Dystrophy Have Similar Features with Inclusion Myopathies , 2012, PloS one.

[22]  M. Dalakas,et al.  Inclusion body myositis and myopathies , 1997, Journal of the Neurological Sciences.

[23]  V. Askanas,et al.  p62/SQSTM1 is overexpressed and prominently accumulated in inclusions of sporadic inclusion-body myositis muscle fibers, and can help differentiating it from polymyositis and dermatomyositis , 2009, Acta Neuropathologica.

[24]  T. Maisonobe,et al.  Diagnostic value of markers of muscle degeneration in sporadic inclusion body myositis , 2011, Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology.

[25]  Steven A Greenberg,et al.  How citation distortions create unfounded authority: analysis of a citation network , 2009, BMJ : British Medical Journal.